Tumour-agnostic drugs in paediatric cancers.
Br J Cancer
; 122(10): 1425-1427, 2020 05.
Article
em En
| MEDLINE
| ID: mdl-32161367
ABSTRACT
The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic. The recently approved drug larotrectinib is an excellent case study of the development of a tumour-agnostic drug relevant to children.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pediatria
/
Proteínas de Fusão Oncogênica
/
Neoplasias
Limite:
Adult
/
Child
/
Humans
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Reino Unido